Patrik Forsell – General Manager, Takeda Denmark
Industry veteran Patrik Forsell oversees Takeda’s operations in Denmark. Here, Forsell talks through how sizeable shifts in the company’s global…
Tagged with Takeda
Rodrigo Rodriguez – General Manager, Middle East Cluster,…
Rodrigo Rodriguez, general manager for Takeda’s Middle East cluster, discusses the company’s ambitions in the collective Saudi pharma market,…
Turkey: A Pharma Talent Hotbed
Drawing on over a dozen interviews with C-level pharmaceutical industry executives in Turkey, PharmaBoardroom has compiled a strategic overview of…
Takafumi Horii – SVP, Head of Japan Oncology Business Unit,…
Experienced global leader Takafumi Horii explains the rationale behind returning to his home nation of Japan to head up Takeda’s Japan Oncology…
Şeyda Atadan Memiş – General Manager, Takeda Turkey
Takeda’s general manager for Turkey, Şeyda Atadan Memiş, reflects on the Japanese giant’s ambitions in Turkey at a pivotal moment when the Shire…
Takeda Pivoting to Growth Amid Renewed Focus on “Core Assets”
“This marks a significant moment in Takeda’s history and is an exciting step forward as we accelerate our transformation journey,” said…
Japan Pharma News: Takeda’s Revenue up 5x; First Domestic…
The latest from Japanese pharma, including Takeda’s big profit jump, British Linepharma’s quest to get the first ever induced abortion pill for…
Building a Health Data Ecosystem in Switzerland
Although Switzerland is ahead of many of its competitors in Europe on levels of healthcare innovation, one potential stumbling block is access to and…
The Long Read: Innovation, Access & Affordability in the USA
A Tale of Two Americas The US stands as the biopharma innovation champion of the world, a global leader on nearly all R&D indices related to…
PharmaBoardroom’s Top Women Leaders 2020
While great strides in gender diversity has been made within healthcare boardrooms and leadership teams globally, as well as more generally across the…
Top 10 PharmaBoardroom Interviews of 2020
2020 was a challenging year globally, but one in which the importance of the healthcare and life sciences sector was underlined like never before.…
Rare Disease Strategies in the Booming US Market
Rare disease – defined in the US as a disease with a maximum patient population of 200,000 – is perhaps the most salient issue at the nexus of…
